• QuickPress

    Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part II)

    In August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a period of approximately six months prior to the announcement.  In Part I of this series, Sujan Rajbhandary, senior member of Mercer Capital’s Financial Reporting Valuation Group, presented a broad outline of the PFE-MDVN transaction.  Part II will delve more into the transaction to present some high-level observations around allocation of the purchase price. To read the full article in Mercer Capital’s Financial Reporting Blog, click: Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation…

  • QuickPress

    Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I)

    In August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a period of approximately six months prior to the announcement.  Sujan Rajbhandary, senior member of Mercer Capital’s Financial Reporting Valuation Group, presents in this blog post (and Part II) a broad outline of the transaction and explore what a potential purchase price allocation would look like. To read the full article in Mercer Capital’s Financial Reporting Blog, click: Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I). This article is republished from Mercer…